Breakthrough T1D Timeline: Stem Cell Therapies
Stem cells have the potential to lead to treatments for type 1 diabetes, but it has taken Breakthrough T1D more…
Vertex Provides an Update on the VX-880 Clinical Trial
Vertex provides an update on their Phase 1/2 Clinical Trial for VX-880, including data from three participants and details around…
The First Gene-Edited Cell Replacement Therapy Takes a Step Forward
The first person has received ViaCyte and CRISPR's cell replacement therapy.
Stem Cell Replacement Therapy: Its Time has Begun
ViaCyte has results on its second stem cell-based technology, providing evidence of stem cells secreting insulin in response to meal…
Progress Toward Cures: Thoughts at Year’s End from Breakthrough T1D’s CEO
Breakthrough T1D CEO Aaron Kowalski, Ph.D., weighs in on the exciting news surrounding stem cell-derived beta cell replacement therapies, now…
First-in-Human Gene-Edited Stem Cell Trial? Check.
ViaCyte, a beta cell replacement company long supported by Breakthrough T1D, and CRISPR Therapeutics have a new first: Gene-editing for…
Vertex Pharmaceuticals Investigating Cell Therapy for Type 1 Diabetes
Vertex is currently enrolling for a clinical trial evaluating their stem cell derived islet cell infusion therapy, VX-880.
Breakthrough T1D & NIH Workshop at the Intersection of Immunology and Bioengineering
Breakthrough T1D and NIH bring together top scientists and engineers to strategize on how to allow implanted beta cells to…
Video: ADA’s Scientific Sessions: Day 4
Here is Dr. Camillo Ricordi to share his key takeaways from day 4 from the American Diabetes Association's Scientific Sessions.
